Home Office Here....

Quote






Good Luck Everyone, today.

Some things to think about when you are wondering WTF is going on. Israel are the main plants for both Respiclick and E-connected devices. Ireland has a huge robotic plant that makes Proair HFA and Qvar and Qnasl. There is an additional large plant with inhaler capabilities in PA. These plants have 1/4 the staff compared to Israeli Union Plants, ie 1/3 the cost to make each inhaler.

No matter what you think is the future of the respiratory products, in the near term the inhaler plants in Israel are closing and manufacturing needs to be shifted. Increasing volume of the DPI devices makes closing those plants a problem. ProAir HFA will be going generic as a Teva Product, made by Teva and it will make Teva 5x more cash than branded due to lack of contracts or rebates for the first couple of years. The first e-connected inhaler got rejected by the FDA needing more data on patient specific concerns, not for failed tech or drug. It will be resubmitted along with the next generation sensor. These drugs WILL NEVER have a large share, but will be sold to MCOs and IDNs who are trying to decrease frequent flyers on government programs where they are losing billions of dollars per year, and will cost a premium.

The Migraine drug data is amazing......Honestly best in class for the CGRP uptake inhibitors. Teva was researching 2 drugs in the class, and just out-licensed the other product for peanuts because this one had better safety and better response by patients. It is fast tracked by the FDA and will launch June-July. Before fast track designation peak sales in 5 years was 1.5-2 billion per year, now that it will hit first, peak sales is 4-6 billion, however, it will need to hit it's launch goals to achieve the goal of replacing copaxone.

Austudo is a MEHHHH drug. Psychs don't write it because they don't treat a drug side effect by writing another drug, they refer to Neuro. So the Psych team's days are numbered calling on their psych targets or doubling up on neuro docs. However, this team will probably switch to headache at these targets and add high volume primary care. Respi reps already have great relationships at some AI and ENTs and Primary Care that also treat Migraines. It makes sense to merge these efforts and increase sales faster.

Take a deep breath....nothing said or done on here can change whats happening. Understand that duplication of effort is what is being eliminated. Unfortunately the new leader of Teva Americas is a former Neuro and Generics guy. He also ran Managed Care, and everyone knows how useless most of those folks are. His cult of personality are made up of and faith are in his former Neuro staff. That made respiratory leadership expendable. These ass-clowns absorbing respiratory have no respiratory experience and do not understand that there are 28,000 prescribers of asthma medication and view everything through the lens that 500 doctors wrote 4 billion a year of copaxone. So expect screwed up target lists, expect push-back on samples and placebos (Not Used in Neuro to train patients), expect misstatements and mispronunciations on the stage at the national sales meeting. Hell, start a drinking game and take a shot at the bar (on your own dime, of course)for each screw up.

Biggest thing is, this all should have happened a few years back and didn't. The fuckers to blame are all Israeli, and thank god, most are gone from the company. And due to their incompetence, here WE are. I hope everyone makes it through ok.
 






anonymous said:
Good Luck Everyone, today.

Some things to think about when you are wondering WTF is going on. Israel are the main plants for both Respiclick and E-connected devices. Ireland has a huge robotic plant that makes Proair HFA and Qvar and Qnasl. There is an additional large plant with inhaler capabilities in PA. These plants have 1/4 the staff compared to Israeli Union Plants, ie 1/3 the cost to make each inhaler.

No matter what you think is the future of the respiratory products, in the near term the inhaler plants in Israel are closing and manufacturing needs to be shifted. Increasing volume of the DPI devices makes closing those plants a problem. ProAir HFA will be going generic as a Teva Product, made by Teva and it will make Teva 5x more cash than branded due to lack of contracts or rebates for the first couple of years. The first e-connected inhaler got rejected by the FDA needing more data on patient specific concerns, not for failed tech or drug. It will be resubmitted along with the next generation sensor. These drugs WILL NEVER have a large share, but will be sold to MCOs and IDNs who are trying to decrease frequent flyers on government programs where they are losing billions of dollars per year, and will cost a premium.

The Migraine drug data is amazing......Honestly best in class for the CGRP uptake inhibitors. Teva was researching 2 drugs in the class, and just out-licensed the other product for peanuts because this one had better safety and better response by patients. It is fast tracked by the FDA and will launch June-July. Before fast track designation peak sales in 5 years was 1.5-2 billion per year, now that it will hit first, peak sales is 4-6 billion, however, it will need to hit it's launch goals to achieve the goal of replacing copaxone.

Austudo is a MEHHHH drug. Psychs don't write it because they don't treat a drug side effect by writing another drug, they refer to Neuro. So the Psych team's days are numbered calling on their psych targets or doubling up on neuro docs. However, this team will probably switch to headache at these targets and add high volume primary care. Respi reps already have great relationships at some AI and ENTs and Primary Care that also treat Migraines. It makes sense to merge these efforts and increase sales faster.

Take a deep breath....nothing said or done on here can change whats happening. Understand that duplication of effort is what is being eliminated. Unfortunately the new leader of Teva Americas is a former Neuro and Generics guy. He also ran Managed Care, and everyone knows how useless most of those folks are. His cult of personality are made up of and faith are in his former Neuro staff. That made respiratory leadership expendable. These ass-clowns absorbing respiratory have no respiratory experience and do not understand that there are 28,000 prescribers of asthma medication and view everything through the lens that 500 doctors wrote 4 billion a year of copaxone. So expect screwed up target lists, expect push-back on samples and placebos (Not Used in Neuro to train patients), expect misstatements and mispronunciations on the stage at the national sales meeting. Hell, start a drinking game and take a shot at the bar (on your own dime, of course)for each screw up.

Biggest thing is, this all should have happened a few years back and didn't. The fuckers to blame are all Israeli, and thank god, most are gone from the company. And due to their incompetence, here WE are. I hope everyone makes it through ok.
Click to expand...


Very nice departing shot from Larry, shortly after his Happy Trails e-mail
 






anonymous said:
Very nice departing shot from Larry, shortly after his Happy Trails e-mail
Click to expand...

The same Larry who a week after the first layoffs stood up at the NSM and said “Lifes too short to drink cheap wine”. You mean that Larry? The one who looks like Captain Kangeroo ? (Google the captain if you don’t know who he is.) the Larry who never had any self awareness? You mean that Larry?
 












anonymous said:
Good Luck Everyone, today.

Some things to think about when you are wondering WTF is going on. Israel are the main plants for both Respiclick and E-connected devices. Ireland has a huge robotic plant that makes Proair HFA and Qvar and Qnasl. There is an additional large plant with inhaler capabilities in PA. These plants have 1/4 the staff compared to Israeli Union Plants, ie 1/3 the cost to make each inhaler.

No matter what you think is the future of the respiratory products, in the near term the inhaler plants in Israel are closing and manufacturing needs to be shifted. Increasing volume of the DPI devices makes closing those plants a problem. ProAir HFA will be going generic as a Teva Product, made by Teva and it will make Teva 5x more cash than branded due to lack of contracts or rebates for the first couple of years. The first e-connected inhaler got rejected by the FDA needing more data on patient specific concerns, not for failed tech or drug. It will be resubmitted along with the next generation sensor. These drugs WILL NEVER have a large share, but will be sold to MCOs and IDNs who are trying to decrease frequent flyers on government programs where they are losing billions of dollars per year, and will cost a premium.

The Migraine drug data is amazing......Honestly best in class for the CGRP uptake inhibitors. Teva was researching 2 drugs in the class, and just out-licensed the other product for peanuts because this one had better safety and better response by patients. It is fast tracked by the FDA and will launch June-July. Before fast track designation peak sales in 5 years was 1.5-2 billion per year, now that it will hit first, peak sales is 4-6 billion, however, it will need to hit it's launch goals to achieve the goal of replacing copaxone.

Austudo is a MEHHHH drug. Psychs don't write it because they don't treat a drug side effect by writing another drug, they refer to Neuro. So the Psych team's days are numbered calling on their psych targets or doubling up on neuro docs. However, this team will probably switch to headache at these targets and add high volume primary care. Respi reps already have great relationships at some AI and ENTs and Primary Care that also treat Migraines. It makes sense to merge these efforts and increase sales faster.

Take a deep breath....nothing said or done on here can change whats happening. Understand that duplication of effort is what is being eliminated. Unfortunately the new leader of Teva Americas is a former Neuro and Generics guy. He also ran Managed Care, and everyone knows how useless most of those folks are. His cult of personality are made up of and faith are in his former Neuro staff. That made respiratory leadership expendable. These ass-clowns absorbing respiratory have no respiratory experience and do not understand that there are 28,000 prescribers of asthma medication and view everything through the lens that 500 doctors wrote 4 billion a year of copaxone. So expect screwed up target lists, expect push-back on samples and placebos (Not Used in Neuro to train patients), expect misstatements and mispronunciations on the stage at the national sales meeting. Hell, start a drinking game and take a shot at the bar (on your own dime, of course)for each screw up.

Biggest thing is, this all should have happened a few years back and didn't. The fuckers to blame are all Israeli, and thank god, most are gone from the company. And due to their incompetence, here WE are. I hope everyone makes it through ok.
Click to expand...

Nailed it!!!!!!
 
























anonymous said:
Good Luck Everyone, today.

Some things to think about when you are wondering WTF is going on. Israel are the main plants for both Respiclick and E-connected devices. Ireland has a huge robotic plant that makes Proair HFA and Qvar and Qnasl. There is an additional large plant with inhaler capabilities in PA. These plants have 1/4 the staff compared to Israeli Union Plants, ie 1/3 the cost to make each inhaler.

No matter what you think is the future of the respiratory products, in the near term the inhaler plants in Israel are closing and manufacturing needs to be shifted. Increasing volume of the DPI devices makes closing those plants a problem. ProAir HFA will be going generic as a Teva Product, made by Teva and it will make Teva 5x more cash than branded due to lack of contracts or rebates for the first couple of years. The first e-connected inhaler got rejected by the FDA needing more data on patient specific concerns, not for failed tech or drug. It will be resubmitted along with the next generation sensor. These drugs WILL NEVER have a large share, but will be sold to MCOs and IDNs who are trying to decrease frequent flyers on government programs where they are losing billions of dollars per year, and will cost a premium.

The Migraine drug data is amazing......Honestly best in class for the CGRP uptake inhibitors. Teva was researching 2 drugs in the class, and just out-licensed the other product for peanuts because this one had better safety and better response by patients. It is fast tracked by the FDA and will launch June-July. Before fast track designation peak sales in 5 years was 1.5-2 billion per year, now that it will hit first, peak sales is 4-6 billion, however, it will need to hit it's launch goals to achieve the goal of replacing copaxone.

Austudo is a MEHHHH drug. Psychs don't write it because they don't treat a drug side effect by writing another drug, they refer to Neuro. So the Psych team's days are numbered calling on their psych targets or doubling up on neuro docs. However, this team will probably switch to headache at these targets and add high volume primary care. Respi reps already have great relationships at some AI and ENTs and Primary Care that also treat Migraines. It makes sense to merge these efforts and increase sales faster.

Take a deep breath....nothing said or done on here can change whats happening. Understand that duplication of effort is what is being eliminated. Unfortunately the new leader of Teva Americas is a former Neuro and Generics guy. He also ran Managed Care, and everyone knows how useless most of those folks are. His cult of personality are made up of and faith are in his former Neuro staff. That made respiratory leadership expendable. These ass-clowns absorbing respiratory have no respiratory experience and do not understand that there are 28,000 prescribers of asthma medication and view everything through the lens that 500 doctors wrote 4 billion a year of copaxone. So expect screwed up target lists, expect push-back on samples and placebos (Not Used in Neuro to train patients), expect misstatements and mispronunciations on the stage at the national sales meeting. Hell, start a drinking game and take a shot at the bar (on your own dime, of course)for each screw up.

Biggest thing is, this all should have happened a few years back and didn't. The fuckers to blame are all Israeli, and thank god, most are gone from the company. And due to their incompetence, here WE are. I hope everyone makes it through ok.
Click to expand...
\


Sorry, great knowledge of Respy products but not as good on the TD marketplace. Psychs are writing, more so than neuros, psych team is really needed and look for respy folks to help on that regard.
 






anonymous said:
Good Luck Everyone, today.

Some things to think about when you are wondering WTF is going on. Israel are the main plants for both Respiclick and E-connected devices. Ireland has a huge robotic plant that makes Proair HFA and Qvar and Qnasl. There is an additional large plant with inhaler capabilities in PA. These plants have 1/4 the staff compared to Israeli Union Plants, ie 1/3 the cost to make each inhaler.

No matter what you think is the future of the respiratory products, in the near term the inhaler plants in Israel are closing and manufacturing needs to be shifted. Increasing volume of the DPI devices makes closing those plants a problem. ProAir HFA will be going generic as a Teva Product, made by Teva and it will make Teva 5x more cash than branded due to lack of contracts or rebates for the first couple of years. The first e-connected inhaler got rejected by the FDA needing more data on patient specific concerns, not for failed tech or drug. It will be resubmitted along with the next generation sensor. These drugs WILL NEVER have a large share, but will be sold to MCOs and IDNs who are trying to decrease frequent flyers on government programs where they are losing billions of dollars per year, and will cost a premium.

The Migraine drug data is amazing......Honestly best in class for the CGRP uptake inhibitors. Teva was researching 2 drugs in the class, and just out-licensed the other product for peanuts because this one had better safety and better response by patients. It is fast tracked by the FDA and will launch June-July. Before fast track designation peak sales in 5 years was 1.5-2 billion per year, now that it will hit first, peak sales is 4-6 billion, however, it will need to hit it's launch goals to achieve the goal of replacing copaxone.

Austudo is a MEHHHH drug. Psychs don't write it because they don't treat a drug side effect by writing another drug, they refer to Neuro. So the Psych team's days are numbered calling on their psych targets or doubling up on neuro docs. However, this team will probably switch to headache at these targets and add high volume primary care. Respi reps already have great relationships at some AI and ENTs and Primary Care that also treat Migraines. It makes sense to merge these efforts and increase sales faster.

Take a deep breath....nothing said or done on here can change whats happening. Understand that duplication of effort is what is being eliminated. Unfortunately the new leader of Teva Americas is a former Neuro and Generics guy. He also ran Managed Care, and everyone knows how useless most of those folks are. His cult of personality are made up of and faith are in his former Neuro staff. That made respiratory leadership expendable. These ass-clowns absorbing respiratory have no respiratory experience and do not understand that there are 28,000 prescribers of asthma medication and view everything through the lens that 500 doctors wrote 4 billion a year of copaxone. So expect screwed up target lists, expect push-back on samples and placebos (Not Used in Neuro to train patients), expect misstatements and mispronunciations on the stage at the national sales meeting. Hell, start a drinking game and take a shot at the bar (on your own dime, of course)for each screw up.

Biggest thing is, this all should have happened a few years back and didn't. The fuckers to blame are all Israeli, and thank god, most are gone from the company. And due to their incompetence, here WE are. I hope everyone makes it through ok.
Click to expand...


Add AD Chester the molester to possible authors of this victim babbling.
Sooooo funny these VPs, SDs, ADs, And RSMs lose no sleep over firing us lowly sales reps BUT when it happens to one of these little bitches they whine and play the poor victim.
Karmas a bitch only if you are one.
 
























Quick questions for all you hard working highly intelligent HO people who are making the move to the new offices...will Teva be paying for your uhauls? Also will you need to take personal days off to do your packing and moving? Have you hired realtors to sell you house yet or will Teva be helping you with that?
Curious minds want to know.
 






anonymous said:
Quick questions for all you hard working highly intelligent HO people who are making the move to the new offices...will Teva be paying for your uhauls? Also will you need to take personal days off to do your packing and moving? Have you hired realtors to sell you house yet or will Teva be helping you with that?
Curious minds want to know.
Click to expand...


How far are the new offices from the old ones? Perhaps they can commute?
 












anonymous said:
So far, very few HO employees have been laid off.
Click to expand...

Correct, just asked to move to a different State in order to keep your job.
Lol
Good luck with the move.
Oh and something to think about, if you do decide to move, what are you going to do once they have more layoffs in a year? Move back to Philly? Or stay in Jersey?
 


















Top Bottom
Back
Quote